Bjrklund, G., Dadar, M., Chirumbolo, S
Again, you just wrote a book to try to help primary care physicians think through this, but how prepared are primary care physicians now to have this kind of conversation in which we consider seriously lifestyle and what that can accomplish, but also we don't just either rush to the GLP-1 or say no, you don't need that
We write this, because the GLP-1 agonists semaglutide, liraglutide, and exenatide each failed to increase beating rate in RA (Neumann et al
The constellation of risk factor improvements provides reasonable expectation of cardiovascular benefit that formal trials may confirm
These nodes are not intrinsically pathological but may become clinically relevant when oxidative demand and substrate availability diverge
Firmer, tighter, younger-looking skin , with no needles, no surgery, and no downtime